Lista de obras -

ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?

artículo científico publicado en 2012

Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis

artículo científico publicado en 2019

Association of HIV Infection with Epilepsy and Other Comorbid Conditions

scientific article published on 01 April 2020

Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report

artículo científico publicado en 2020

Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older

artículo científico publicado en 2018

Clinical features and outcomes of HIV patients with coronavirus disease 2019

artículo científico publicado en 2020

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

artículo científico publicado en 2011

Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients

artículo científico publicado en 2015

Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing

artículo científico publicado en 2012

Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study

artículo científico publicado en 2015

Determinants of bone diseases in tenofovir-treated HIV patients.

artículo científico publicado en 2016

Different effects of glucocorticoids on darunavir plasma concentrations

scientific article published on 09 January 2019

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

artículo científico publicado en 2016

Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy

artículo científico publicado en 2020

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study

artículo científico publicado en 2020

Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF.

artículo científico publicado en 2017

Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference

artículo científico publicado en 2017

Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report

scientific article published on 03 January 2020

Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice

article

How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?

artículo científico publicado en 2017

Immune deficiency is a risk factor for severe COVID-19 in people living with HIV

artículo científico publicado en 2020

Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review

artículo científico publicado en 2020

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study

artículo científico publicado en 2002

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects

artículo científico publicado en 2011

Is it time to revise linezolid doses in peritoneal dialysis patients? A case series

artículo científico publicado en 2015

Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?

artículo científico publicado en 2016

Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology

artículo científico

Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics

artículo científico publicado en 2013

Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

artículo científico publicado en 2011

Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring

artículo científico publicado en 2015

Liver Injury After Occasional Energy Drink Use in a Patient Living With HIV and Diabetes

scientific article published on 18 October 2019

Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?

scientific article published on 14 May 2020

Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?

scientific article published on 01 August 2018

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

artículo científico publicado en 2013

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?

artículo científico publicado en 2015

Multidrug-resistant HIV viral rebound during early syphilis: a case report

scientific article published on 07 April 2020

Orlistat: weight lost at cost of HIV rebound

artículo científico publicado en 2016

Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors

artículo científico publicado en 2017

Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients

artículo científico publicado en 2014

Prolonged inductive effect of rifampicin on linezolid exposure

artículo científico publicado en 2015

Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?

artículo científico publicado en 2016

Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy

artículo científico publicado en 2015

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study

artículo científico publicado en 2020

Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction

artículo científico publicado en 2016

Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.

artículo científico publicado en 2015

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers

scientific article published on 02 June 2012

The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection

artículo científico publicado el 30 de junio de 2012

Therapeutic drug management of linezolid: a missed opportunity for clinicians?

artículo científico publicado en 2016

When food can make the difference: The case of elvitegravir-based co-formulation

artículo científico publicado en 2016

Lista de obras de

ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?

Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis

Association of HIV Infection with Epilepsy and Other Comorbid Conditions

Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report

Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older

Clinical features and outcomes of HIV patients with coronavirus disease 2019

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients

Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing

Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study

Determinants of bone diseases in tenofovir-treated HIV patients.

Different effects of glucocorticoids on darunavir plasma concentrations

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study

Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF.

Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference

Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report

Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice

How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?

Immune deficiency is a risk factor for severe COVID-19 in people living with HIV

Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects

Is it time to revise linezolid doses in peritoneal dialysis patients? A case series

Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?

Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology

Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics

Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring

Liver Injury After Occasional Energy Drink Use in a Patient Living With HIV and Diabetes

Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?

Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?

Multidrug-resistant HIV viral rebound during early syphilis: a case report

Orlistat: weight lost at cost of HIV rebound

Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors

Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients

Prolonged inductive effect of rifampicin on linezolid exposure

Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?

Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study

Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction

Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers

The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection

Therapeutic drug management of linezolid: a missed opportunity for clinicians?

When food can make the difference: The case of elvitegravir-based co-formulation